ofa vs fda tirzepatide FDA's Removal of Semaglutide and the Evolving Decisions: What Compounders Need to Know Where things stand (for now): – Lilly seeks to intervene in

Although causality is debated and absolute risk is low, clinicians should be alert to severe abdominal pain and elevated pancreatic enzymes and stop therapy if pancreatitis is suspected

Many people do better with smaller, balanced meals rather than large portions

For patients taking warfarin, more frequent INR monitoring is recommended during semaglutide initiation or dose changes, as a prudent clinical practice

Improvement of at least one fibrosis stage without worsening of MASH occurred in 51-55% of tirzepatide-treated participants versus 30% with placebo

[54] Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F.,